Enlicitide eligibility criteria for high cholesterol patients

Two days after approval, the practical question is not whether enlicitide is novel. It is whether the patient in front of you is actually inside the approved and evidence-supported lane: an adult with hypercholesterolemia, including possible heterozygous familial hypercholesterolemia, still above an LDL-C threshold despite appropriate background therapy.

The compact answer is this: enlicitide, marketed as Lipfendra, is an FDA-approved oral PCSK9 inhibitor given as 20 mg once daily for adults with hypercholesterolemia, including adults with HeFH, as an adjunct to diet and exercise.[1] In the CORALreef eligibility framework, the LDL-C threshold depends on risk category: at least 55 mg/dL for patients with prior major ASCVD events, and at least 70 mg/dL for intermediate-to-high-risk patients without prior events.[2] The pivotal trial population was also anchored to stable moderate- or high-intensity statin therapy, or documented statin intolerance.[2][3]

That means an LDL-C value alone is not enough to clear a patient. The clinician still has to answer three operational questions: which prevention category applies, whether the background lipid regimen is adequate and stable, and whether any trial exclusion makes the patient a poor match for the data.

The First Split Is Secondary Versus Primary Prevention

For enlicitide eligibility in high cholesterol, the cleanest starting point is the LDL-C threshold, because the threshold changes with ASCVD history. In CORALreef Lipids, patients with prior major ASCVD events entered at a lower LDL-C cutoff: 55 mg/dL or higher.[2] Patients without prior events, but considered intermediate to high risk for a first event, entered at 70 mg/dL or higher.[2]

This is where prescribing errors can start. A patient with diabetes, hypertension, and persistent LDL-C of 62 mg/dL may feel clinically concerning, but if there has been no prior major ASCVD event, the CORALreef primary-prevention threshold was 70 mg/dL, not 55 mg/dL.[2] Conversely, a post-MI patient at 58 mg/dL remains above the secondary-prevention trial threshold. The number has to be interpreted after the risk category is settled.

The FDA indication is broader than a single trial entry table, but the trial thresholds are still the best available map for evidence-based patient selection immediately after approval. They help distinguish an approved adult hypercholesterolemia population from the narrower group in whom LDL-C lowering was studied under controlled entry rules.

Background Therapy Has To Be Reconciled Before Eligibility Is Claimed

Enlicitide should not be presented as a replacement for basic lipid management. The FDA-approved indication describes use as an adjunct to diet and exercise.[1] The pivotal CORALreef program also required patients to be on stable moderate- or high-intensity statin therapy, or to have documented statin intolerance.[2][3]

For the person doing medication reconciliation, that means the statin history matters as much as the LDL-C result. The chart should make clear whether the patient is on a moderate- or high-intensity statin, whether the dose has been stable, and whether intolerance is documented rather than assumed. A note that says “failed statins” without agent, dose, timing, and reaction may be clinically familiar, but it is weak support for matching the pivotal trial population.

Nonstatin background therapy is also part of the real-world picture, although the eligibility question should not drift into a full sequencing algorithm. The narrow point is simpler: before labeling a patient as a candidate for enlicitide, confirm that persistent LDL-C elevation is being measured against an appropriate existing lipid-lowering regimen, not against undertreatment, nonadherence, or an unresolved intolerance history.

Exclusions That Can Remove an Apparently Eligible Patient

Several patients will look eligible if the review stops at age, diagnosis, LDL-C, and statin use. The CORALreef exclusion criteria narrow that group. Key exclusions included homozygous familial hypercholesterolemia, compound or double heterozygous familial hypercholesterolemia, heart failure hospitalization within 3 months, prior PCSK9 inhibitor use without adequate washout, LDL apheresis within 3 months, and fasting triglycerides of at least 400 mg/dL.[3][4]

• HoFH or compound/double heterozygous FH: do not generalize the HeFH evidence to these higher-risk genetic categories.
• Recent heart failure hospitalization: a hospitalization within 3 months placed patients outside the pivotal trial frame.
• Prior PCSK9 inhibitor exposure: check whether injectable PCSK9 therapy was used and whether the required washout logic is satisfied.
• LDL apheresis: apheresis within 3 months was an exclusion, so recent treatment can make the LDL-C value and eligibility interpretation less straightforward.
• Fasting triglycerides ≥400 mg/dL: this threshold excluded patients and should prompt cleanup of the lipid assessment before using LDL-C entry logic.

The HoFH point deserves explicit handling because it is easy to blur familial hypercholesterolemia categories. The adult indication includes HeFH.[1] The available CORALreef eligibility material does not support treating HoFH, compound heterozygous FH, or double heterozygous FH as covered by the same evidence base.[3][4] A lipid specialist may still need to solve those patients’ LDL-C problem, but this approval and trial map should not be stretched to do it.

Prior injectable PCSK9 inhibitor use is another chart-review trap. A patient may be referred because injections were unaffordable, intolerable, inconvenient, or simply abandoned. That history is clinically relevant, but it does not automatically make the patient a clean match for enlicitide trial criteria. The washout question has to be answered, especially if recent LDL-C values were influenced by an injectable PCSK9 inhibitor.

A Practical Eligibility Map

For a busy clinic, the most useful way to apply the evidence is to narrow the patient step by step. This is an eligibility judgment, not a recommendation to prescribe.

1. Confirm adult status and diagnosis: adult with hypercholesterolemia, including possible HeFH, within the FDA-approved population.
2. Assign risk category: prior major ASCVD event uses the ≥55 mg/dL LDL-C threshold; intermediate-to-high-risk primary prevention uses the ≥70 mg/dL threshold.
3. Verify the current LDL-C value: use the appropriate threshold after risk category is assigned, not before.
4. Reconcile background therapy: document stable moderate- or high-intensity statin therapy, or a defensible statin intolerance history.
5. Screen exclusions: HoFH or compound/double heterozygous FH, recent heart failure hospitalization, unresolved prior PCSK9 inhibitor washout, recent LDL apheresis, and fasting triglycerides ≥400 mg/dL.
6. Separate LDL-C lowering from outcomes: recognize that cardiovascular event reduction has not yet been demonstrated for enlicitide.

This sequence prevents the common shortcut: “LDL still high, oral PCSK9 now available.” The better formulation is narrower: “adult patient, correct prevention category, above the applicable LDL-C threshold, on appropriate background therapy or documented intolerant, and not excluded by the trial logic.”

What the Approval Does Not Yet Answer

The approval establishes enlicitide as an oral option for selected adults with hypercholesterolemia, including HeFH.[1] It does not establish pediatric use. CORALreef Pediatric is enrolling patients ages 6 to 17 years with HeFH, but those data are pending.[5]

It also does not answer coverage and access questions. As of July 18, 2026, pricing and insurance coverage details were not available in the materials reviewed. That matters because an oral drug may reduce injection burden without eliminating prior authorization work, formulary restrictions, or documentation requirements.

Concurrent use with injectable PCSK9 inhibitors should not be assumed. The available materials do not provide data supporting routine combination with injectable PCSK9 therapy, and the trial criteria treated prior PCSK9 inhibitor exposure as a washout issue rather than a concurrent-use model.[3][4]

Longer-term safety and cardiovascular outcomes remain separate questions. Available pivotal safety follow-up is limited to 52 weeks in the reviewed materials.[2][3] CORALreef Outcomes is designed to study major adverse cardiovascular events in more than 14,500 patients, with estimated completion in November 2029.[6] Until those results are available, enlicitide should be described as LDL-C-lowering therapy, not as outcomes-proven cardiovascular event prevention.

The eligibility conclusion is therefore deliberately narrow: enlicitide is an FDA-approved oral PCSK9 inhibitor option for selected adults with hypercholesterolemia, including HeFH, who remain above risk-stratified LDL-C thresholds on appropriate background therapy or with documented statin intolerance, and who do not fall into key excluded groups. That is enough to identify a candidate. It is not enough to claim demonstrated reduction in cardiovascular events.

References

1. FDA Approves First Oral PCSK9 Inhibitor for Adults With Hypercholesterolemia. U.S. Food and Drug Administration. July 16, 2026.
2. Oral PCSK9 Inhibitor Enlicitide in Hypercholesterolemia. New England Journal of Medicine. 2026.
3. Enlicitide Decanoate Added to Lipid-Lowering Therapy in Patients With Hypercholesterolemia: The CORALreef AddOn Trial. Journal of the American College of Cardiology. 2026.
4. A Study of Enlicitide Decanoate (MK-0616) in Adults With Hypercholesterolemia (MK-0616-015). ClinicalTrials.gov.
5. A Study of Enlicitide Decanoate in Pediatric Participants With Heterozygous Familial Hypercholesterolemia. ClinicalTrials.gov.
6. A Study of Enlicitide Decanoate (MK-0616) in Adults at High Cardiovascular Risk (MK-0616-017). ClinicalTrials.gov.